A Study on the Recurrence Factors of Endometrial Lesions in Patients Undergoing Hysteroscopy After Breast Cancer Surgery

Objective Patients receiving endocrine therapy after breast cancer surgery exhibit a high incidence of endometrial lesions, yet corresponding measures to prevent recurrence of lesions remain inadequate. This study aims to investigate the correlation between endometrial lesion recurrence and multiple factors, with the goal of reducing recurrence risks and improving patient outcomes.

Retrospective analysis of clinical data of 314 patients with breast cancer who underwent hysteroscopy after surgery was reviewed from August 2014 to August 2024. The status of ultrasound follow-up in these patients after hysteroscopic treatment was retrospectively reviewed to determine the recurrence outcomes. The column chart predicting endometrial lesion recurrence risk was constructed by R language. The Kaplan–Meier Curve and Log-Rank Test were employed to further analyze the correlation between medication duration and endometrial recurrence risk.

The recurrence rate of endometrial lesions in toremifene (TOR) group was significantly higher (78.6% VS control group: 12.4%), and the usage of TOR, age, non-benign endometrial lesions, increased endometrial thickness, increased size of polyps, history of adenomyosis and uterine fibroids were significantly correlated with the recurrence rate of endometrial lesions. Survival analysis showed a median recurrence-free survival time of 49 months for patients using TOR.

Patients using TOR are prone to endometrial lesions, especially young patients who use TOR drugs for a long time. The larger the polyp and the thicker the endometrium, the higher the risk of recurrence of endometrial lesions. Furthermore, enhanced endometrial monitoring is recommended during the initial four-year high-risk period. Similar content being viewed by others

MicReferenceshaels E, Worthington RO, Rusiecki J. Breast cancer: risk assessment, screening, and primary prevention. Med Clin North Am. 2023;107:271–84. Takagi K, Yamaguchi M, Miyashita M, et al. Diverse role of androgen action in human breast cancer. Endocr Oncol. 2022;2(1):R102–11. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. Rani A, Stebbing J, Giamas G, et al. Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy. Front Endocrinol (Lausanne). 2019;10:245. Wang X, Wang C, Guan J, et al. Progress of breast cancer basic research in China. Int J Biol Sci. 2021;17(8):2069–79. Breast Cancer Expert Committee of National Cancer Quality Control Center, Breast Cancer Expert Committee of China Anti-Cancer Association, Cancer Drug Clinical Research Committee of China Anti-Cancer Association. Chin J Oncology. Zhonghua Zhong Liu Za Zhi. 2024;46:1079–1106. Ryu KJ, Kim MS, Lee JY, et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open. 2022;5(11):e2243951. Hu R, Clarke LH, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (review). Oncol Lett. 2015;9(4):1495–501. Li YH, He Y, Wu YM. Research progress on the influence and monitoring of endometrium in breast cancer patients after endocrine therapy. J Chin Oncol. 2019;25(3):261–3. Special Committee on Oncological Endocrinology of China Anti-Cancer Association. Guidelines for the management of endometrial lesions associated with adjuvant endocrine therapy for breast cancer. Chin J Pract Gynecol Obstet. 2021;37(8):815–20. Zhou Q, Zhang SQ, Wang XH, et al. Breast cancer endocrine adjuvant therapy-related endometrial lesions management guidelines. Chin J Pract Gynecol Obstet. 2021;37(8):815–20. Wang QQ, Wang XL, Pan SY, et al. Research progress on premenopausal, postmenopausal and tamoxifen-associated endometrial polyps. Int J Gynecol Obstet. 2024;51(2):137–41. Vahdat M, Mousavi AS, Kaveh M, et al. Hysteroscopic polypectomy with endometrial resection preventing the recurrence of endometrial polyps: a single-blinded randomized clinical trial. Caspian J Intern Med. 2022;13(2):393–7. Liu J, Liang Y, Ouyang J, et al. Analysis of risk factors and model establishment of recurrence after endometrial polypectomy. Ann Palliat Med. 2021;10(11):11628–34. Preutthipan S, Herabutya Y. Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women. Fertil Steril. 2005;83(3):705–9. Ciscato A, Zare SY, Fadare O. The significance of recurrence in endometrial polyps: a clinicopathologic analysis. Hum Pathol. 2020;100:38–44. Yang JH, Chen CD, Chen SU, et al. Factors influencing the recurrence potential of benign endometrial polyps after hysteroscopic polypectomy. PLoS ONE. 2015;10(12):e0144857. Chowdary P, Maher P, Ma T, et al. The role of the mirena intrauterine device in the management of endometrial polyps: a pilot study. J Minim Invasive Gynecol. 2019;26(7):1297–302. Gu F, Zhang H, Ruan S, et al. High number of endometrial polyps is a strong predictor of recurrence: findings of a prospective cohort study in reproductive-age women. Fertil Steril. 2018;109(3):493–500. Paradisi R, Rossi S, Scifo MC, et al. Recurrence of endometrial polyps. Gynecol Obstet Invest. 2014;78(1):26–32. Bueloni-Dias FN, Spadoto-Dias D, Nahas Neto J, et al. Predictive factors for occurrence of endometrial polyps in postmenopausal women. Rev Bras Ginecol Obstet. 2014;36(11):489–96. Vitale SG, Haimovich S, Lagana AS, et al. Endometrial polyps an evidence-based diagnosis and management guide. Eur J Obstet Gynecol Reprod Biol. 2021;260:70–7. National Health Commission of the People’s Republic of China. Guidelines for weight management. Office of the National Health Commission, Beijing. 2024. Fang RL, Chen LX, Shu WS, et al. Barcoded sequencing reveals diverse intrauterine microbiomes in patients suffering with endometrial polyps. Am J Transl Res. 2016;8(3):1581–92. Ren H, Duan H, Wang S, et al. Hysteroscopy combined with laser vaporesection for endometrial polyps. J Invest Surg. 2022;35(10):1772–8. Funding There are no funds in this article. Author information Authors and Affiliations Contributions Conceptualization, Xinyue Chen and Rongying Ou; Methodology, Xinyue Chen; Software, Xinyue Chen and Qian Zhang; Validation, Qian Zhang; Visualization, Xinyue Chen; Writing—original draft, Xinyue Chen; Writing—review and editing, Rongying Ou. Corresponding author Ethics declarations Conflict of interests The authors declare that they have no competing interests. Ethical Approval This study has been approved by the Clinical Research Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University (ethical number: KY-2025R190). Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xinyue Chen is a Physician; Qian Zhang is a Physician; Rongying Ou is a Chief Physician. Rights and permissions Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. About this article Cite this article Chen, X., Zhang, Q. & Ou, R. A Study on the Recurrence Factors of Endometrial Lesions in Patients Undergoing Hysteroscopy After Breast Cancer Surgery. J Obstet Gynecol India (2026). https://doi.org/10.1007/s13224-026-02360-4 Received: Accepted: Published: Version of record: DOI: https://doi.org/10.1007/s13224-026-02360-4